Gujarat Magazine

Creative Biolabs Provides Next-Generation Probiotics-Based Drug Discovery Services

 Breaking News
  • No posts were found

Creative Biolabs Provides Next-Generation Probiotics-Based Drug Discovery Services

January 19
06:54 2024
In its pursuit of discovering next-generation drugs based on probiotics, Creative Biolabs is recognized as a trusted partner across the globe thanks to its extensive knowledge, vast experience, and comprehensive, hands-on approach.

New York, USA – January 18, 2024 – Research indicates that NGPs can target specific diseases and function therapeutically, similar to traditional drugs. This field of study has garnered significant interest due to advancements in genetic sequencing tools, bioinformatics platforms, and more powerful technologies for modifying bacterial genomes. These developments have spurred the investigation into new probiotic strains and their potential applications in biomedical research. Creative Biolabs has been dedicated to live biotherapeutics drug discovery for years, providing comprehensive probiotics-based drug discovery services and a portfolio of probiotic strains.

One of the highlighted species in the portfolio is Bifidobacterium bifidum, known for its positive impact on gut health and immune system modulation. Creative Biolabs is committed to exploring the therapeutic potential of Bifidobacterium bifidum in novel drug discovery and development, along with various products of Bifidobacterium bifidum for research use.

Clostridium spp, another key focus of Creative Biolabs’ research, holds promise in various applications, including the treatment of infections and metabolic disorders. Scientists at this company are devoted to providing a series of excellent services to accelerate research in Clostridium-based therapies.

In addition to the two probiotics mentioned above, Blautia producta and Enterococcus faecalis are provided by this company. An expert at Creative Biolabs commented, “Recent studies have indicated that E.faecalis strains are beneficial in treating patients with Parkinson’s disease and inflammatory bowel disease (IBD), as well as other types of diseases.”

Creative Biolabs has established a panel of assays to develop various types of E. faecalis-based NGPs for human disease therapies and provides high-quality Blautia producta, aiming to help develop groundbreaking solutions for various health conditions.

According to a scientist at Creative Biolabs, “Next-generation probiotics have great potential in the treatment of different diseases, such as colitis, metabolic syndromes, diabetes mellitus, liver diseases, cardiovascular diseases, and also cancer and neurodegenerative diseases. We have developed diverse NGPs to contribute to the research of NGPs-based drug discovery.”

For more information about NGP-based drug discovery services at Creative Biolabs, please visit

About Creative Biolabs

Creative Biolabs, a distinguished expert in the arena of live biotherapeutics drug discovery, has wholeheartedly committed itself to the field. With a wealth of practical field experience, the company has provided pivotal assistance to customers actively engaged in discovering next-generation probiotics-based drugs, successfully driving many customer research projects with significantly improved outputs.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States